$599

Zafgen Q4 ’18 Earnings Update; ZGN-1258 Discontinued in PWS

Yesterday, Zafgen hosted its Q4 ’18 earnings call and discussed its pathway to have FDA remove the clinical hold on ZGN-1061, its novel MetAP2 inhibitor for the treatment of T2DM. Additionally, Zafgen disclosed it has discontinued development of ZGN-1258 for the development of Prader-Willi Syndrome due to unforeseen findings in rat toxicity studies. Below are highlights and insights from the call.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.